HomeCompareTHYCY vs MRK

THYCY vs MRK: Dividend Comparison 2026

THYCY yields 2.16% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $22.5K in total portfolio value
10 years
THYCY
THYCY
● Live price
2.16%
Share price
$5.43
Annual div
$0.12
5Y div CAGR
26.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.2K
Annual income
$3,607.02
Full THYCY calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — THYCY vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHYCYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THYCY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THYCY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THYCY
Annual income on $10K today (after 15% tax)
$183.32/yr
After 10yr DRIP, annual income (after tax)
$3,065.97/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $5,530.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THYCY + MRK for your $10,000?

THYCY: 50%MRK: 50%
100% MRK50/50100% THYCY
Portfolio after 10yr
$46.5K
Annual income
$6,860.40/yr
Blended yield
14.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

THYCY
No analyst data
Altman Z
1.5
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THYCY buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHYCYMRK
Forward yield2.16%2.81%
Annual dividend / share$0.12$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR26.4%32.7%
Portfolio after 10y$35.2K$57.7K
Annual income after 10y$3,607.02$10,113.78
Total dividends collected$13.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: THYCY vs MRK ($10,000, DRIP)

YearTHYCY PortfolioTHYCY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,973$272.61$11,213$373.04$240.00MRK
2$12,094$353.36$12,667$512.06$573.00MRK
3$13,401$460.09$14,439$708.14$1.0KMRK
4$14,941$602.23$16,640$988.16$1.7KMRK
5$16,780$793.18$19,432$1,394.07$2.7KMRK
6$19,007$1,052.33$23,057$1,992.90$4.0KMRK
7$21,746$1,408.10$27,889$2,894.79$6.1KMRK
8$25,171$1,903.07$34,518$4,286.29$9.3KMRK
9$29,535$2,602.23$43,912$6,494.35$14.4KMRK
10$35,209$3,607.02$57,714$10,113.78$22.5KMRK

THYCY vs MRK: Complete Analysis 2026

THYCYStock

Taiheiyo Cement Corporation engages in the cement, mineral resources, environmental, and construction materials businesses in Japan and internationally. The company's Cement segment offers ordinary Portland cement, specialty cement, soil stabilizers, and ready-mixed concrete. Its Mineral Resources segment sells limestone aggregate products comprising course and fine aggregate used in ready-mixed concrete, and aggregate used in concrete products and civil engineering; sandstone and andesite as aggregate materials; quicklime, slaked lime, filler, silica, and silica powder; and hollow ceramics, sepiolite, wollastonite, and kaolin, as well as recycles surplus construction soil. The company's Environmental segment recycles used tires, waste plastics, paper sludge, waste casting sand, other industrial waste, surplus soil from water purification, sewage sludge, dredging sludge, and other wastes discarded from municipalities, as well as engages in the CFC treatment and building waste treatment plants; develops and commercializes environmental recycling technologies, including ash washing system and applied kiln system; supplies flue gas desulfurization materials, such as calcium carbonate to coal-fired power plants; and sells slag powder and other inorganic materials, coal, heavy oil, and other fuels, as well as chemicals and gypsum. Its Construction Materials segment produces precast concrete products; promenades, interlocking blocks, and concrete housing products; acoustic panels used to reduce construction noise; and fireproof covering materials used in tunnels. The company's Other Businesses segment leases land for office buildings, commercial stores, leisure facilities, distribution warehouses, and other structures, as well as develops land for residential housing; and engages in the data processing, transportation and warehouse, engineering, chemical products, and sports businesses. Taiheiyo Cement Corporation was incorporated in 1881 and is headquartered in Tokyo, Japan.

Full THYCY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this THYCY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THYCY vs SCHDTHYCY vs JEPITHYCY vs OTHYCY vs KOTHYCY vs MAINTHYCY vs JNJTHYCY vs ABBVTHYCY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.